LAUSANNE, Switzerland & SHANGHAI—AC Immune SA and WuXi Biologics teamed up in recent months under the umbrella of an exclusive strategic collaboration focused on the discovery, development and manufacturing of biologics. The companies inked a memorandum of understanding for a preferred partnership that grants AC Immune access to WuXi Biologics’ platforms in manufacturing and supplying traditional and novel New Biological Entities against CNS disorders. WuXi will become a preferred partner for AC Immune for bioprocess development and manufacturing. The agreement also covers the potential use of AC Immune’s platform to treat non-CNS diseases, and the potential for WuXi Vaccines, the vaccine arm of WuXi Biologics, to apply AC Immune’s vaccine portfolio in China.